Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 12/20 | 0.39 |
| ▸ | BRD2 | P25440 | 7/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907803 | 0.87 | BRD4 (0.48) | BRD4BRD2BRD3ATAD2NR3C1 | |
| SCHEMBL1906132 | 0.87 | BRD4 (0.48) | BRD4BRD2BRD3ATAD2NR3C1 | |
| SCHEMBL29619075 | 0.80 | BRD4 (0.45) | MAP4K4BRD4BRD2BRD3ATAD2 | |
| SCHEMBL11980660 | 0.80 | BRD4 (0.47) | MAP4K4BRD4BRD2BRD3ATAD2 | |
| SCHEMBL16896898 | 0.78 | BRD4 (0.48) | BRD4BRD2BRD3ATAD2NR3C1 | |
| SCHEMBL16118502 | 0.77 | ERN1 (0.48) | MAP4K4BRD4BRD2BRD3ATAD2 | |
| SCHEMBL18249941 | 0.77 | FFAR1 (0.43) | MAP4K4BRD4BRD2BRD3ATAD2 | |
| SCHEMBL18249919 | 0.77 | NR3C1 (0.43) | MAP4K4BRD4BRD2BRD3ATAD2 | |
| SCHEMBL17467704 | 0.77 | AKR1C3 (0.41) | BRD4BRD2BRD3NR3C1ALDH1A1 | |
| SCHEMBL16619524 | 0.76 | ATAD2 (0.46) | BRD4BRD2BRD3ATAD2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | MAP4K4 1675/4885BRD4 4/4885BRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.